NCT05784441View on ClinicalTrials.gov

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

October 30, 2037

Study Completion Date

February 25, 2039

Conditions
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Interventions
DRUG

JNJ-90009530

JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20

Trial Locations (15)

2050

RECRUITING

Royal Prince Alfred Hospital, Camperdown

2145

RECRUITING

Westmead Hospital, Westmead

3084

RECRUITING

Austin Hospital, Heidelberg

3168

RECRUITING

Monash Medical Centre, Clayton

4029

RECRUITING

Royal Brisbane and Women's Hospital, Herston

19104

COMPLETED

University of Pennsylvania, Philadelphia

40506

RECRUITING

University of Kentucky, Lexington

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

52242

RECRUITING

University of Iowa Hospital, Iowa City

55905

COMPLETED

Mayo Clinic Rochester, Rochester

77030

RECRUITING

MD Anderson Cancer Center, Houston

5266202

RECRUITING

Sheba Medical Center, Ramat Gan

9112001

RECRUITING

Hadassah Medical Center, Jerusalem

08901

RECRUITING

Rutgers University, New Brunswick

NW1 2BU

RECRUITING

University College London Hospitals, London

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY